Lipids & metabolic liver disease
The burden and mortality impact of cardiovascular disease–metabolic dysfunction–associated steatotic liver disease comorbidity
Authors' conclusion
CVD-MASLD comorbidity is an emerging global concern associated with excess mortality, emphasizing the need to incorporate MASLD screening and fibrosis evaluation into cardiovascular prevention strategies.
Study context
- Population
- Global Burden of Disease (GBD) 2023 data (1990–2023) for trends; NHANES participants for mortality associations
- Exposure
- CVD-MASLD comorbidity vs no comorbidities
- Outcome
- Mortality, CVD-MASLD comorbidity vs no comorbidities
Methodological detailsmultivariable and survival models, population attributable fraction analyses
- Multivariable and survival models
- Population attributable fraction analyses
Main finding
As reported in the abstract
AHR, all-cause mortality
1.68
CVD-MASLD comorbidity
AHR, cardiovascular mortality
2.68
CVD-MASLD comorbidity
Observational data: associations, not effects.
Further findings
| Outcome | CVD-MASLD comorbidity | CVD | MASLD |
|---|---|---|---|
| Population attributable fraction of cardiovascular deaths | 7.8% | 13.3% | 1.3% |
- Population attributable fraction of cardiovascular deaths — Total PAF
- 22.4%
Global burden trends 1990–2023
- Global cardiovascular disease (CVD) burden declined steadily while MASLD rose continuously, with divergent and regionally heterogeneous trends
- In high-income countries CVD indicators decreased despite rising MASLD burden; inverse pattern weaker in upper-middle-income regions
Mortality by fibrosis severity
- Mortality rose progressively with fibrosis severity
Population attributable fraction of cardiovascular deaths
- Marked age-related heterogeneity of associations
Original publication
The burden and mortality impact of cardiovascular disease–metabolic dysfunction–associated steatotic liver disease comorbidity. Diabetes Res Clin Pract. Published 7 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →